Cognition Therapeutics, Inc.
NASDAQ:CGTXBiotechnology
-$0.01 today
- Market cap
- $57.06M
- Beta
- 1.75
- P/E (TTM)
- -6.4
- EPS (TTM)
- -$0.22
Volume 0.34M
Average 1.23M
CGTX Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Cognition Therapeutics, Inc.NASDAQ: CGTX
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income declines year over year
Q1 FY2026 net income of $4.57M (cash outflow) fell 46.1% year over year, behind the -41.2% change in trailing-twelve-month net income. Sequentially, it rose 36.7% from the prior quarter. Over 3 fiscal years it compounded at +3.2% a year.
Context
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 2 analysts of -$32.22M (+37.2%) for the fiscal year ending Dec 2026, a step up from the -30.9% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$4.57M+36.7% QoQ
- Last fiscal yearDec 2025
- -$23.49M-30.9% YoY
- LTMMar 2026
- -$19.58M-41.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -46.1% | -17.2% | +28.9 pp |
| 1 year | -30.9% | +37.2% | +68.1 pp |
| 3-year CAGR | +3.2% | +10.0% | +6.9 pp |
| 5-year CAGR | -0.8% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (23.49M) USD
- Year-over-year change
- +30.9%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (23.49M) | +30.9% |
| FY2024 | 2024-12-31 | (33.97M) | -31.7% |
| FY2023 | 2023-12-31 | (25.79M) | -20.5% |
| FY2022 | 2022-12-31 | (21.4M) | -82.6% |
| FY2021 | 2021-12-31 | (11.72M) | — |
Net Income vs competitors
How CGTX compares with its peers on the latest reported figures
- CGTX's LTM Mar 2026 net income of $19.58M is the 7th largest of the 8 companies compared; the peer median is $46.9M.
- Its year-over-year change of -41.2% is the 7th highest of 8, against a peer median of +82.4%.
- Over three fiscal years its annual growth of +3.2% compares with a peer median of +17.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $342.56M | +319.3% | +88.7% | 4571.1% | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $106.93M | +82.4% | — | 892.4% |
| LTM Mar 2026 | $70.49M | -17.9% | -7.5% | 468.7% | |
| LTM Mar 2026 | $62.51M | +132.2% | +0.2% | 50.5% | |
| LTM Mar 2026 | $46.9M | -164.3% | — | 4088.8% | |
| LTM Mar 2026 | $21.76M | +31.3% | +35.2% | — | |
| LTM Mar 2026 | $19.58M | -41.2% | +3.2% | — | |
| LTM Mar 2026 | $15.24M | +121.8% | — | 27.8% | |
| Peer median (excluding CGTX) | $46.9M | +82.4% | +17.7% | 680.6% | |
Competitors are the stored peer set for CGTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (11.72M) | (21.4M) | (25.79M) | (33.97M) | (23.49M) |
| Depreciation & Amortization | 93K | 235K | 252K | 266K | 228K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.18M | 3.57M | 4.35M | 3.75M | 2.09M |
| Change in Working Capital | 2.84M | (943K) | 4.85M | 1.29M | (3.46M) |
| Accounts Receivables | (1.11M) | (1.41M) | 2.39M | (1.41M) | (7.24M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.17M | (1.09M) | 0 | 0 | 3.51M |
| Other Working Capital | 1.79M | 1.56M | 2.46M | 2.69M | 270K |
| Other Non-Cash Items | (33K) | 0 | 318K | 195K | 41K |
| Operating Cash Flow | (3.63M) | (18.53M) | (16.02M) | (28.47M) | (24.59M) |
| Capital Expenditures | (27K) | (171K) | (147K) | (4K) | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 9K |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (27K) | (171K) | (147K) | (4K) | 9K |
| Debt Repayment | (268K) | (1.4M) | (811K) | (739K) | (353K) |
| Common Stock Issued | 44.22M | 5.32M | 5.33M | 24.35M | 37.09M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 9.25M | 1.62M | 0 | (46K) | (164K) |
| Financing Cash Flow | 53.2M | 5.55M | 4.52M | 23.57M | 36.57M |
| Effect of Forex Changes | (11K) | (1K) | 4K | 0 | 0 |
| Net Change in Cash | 49.53M | (13.16M) | (11.64M) | (4.91M) | 11.99M |
| Free Cash Flow | (3.66M) | (18.7M) | (16.17M) | (28.48M) | (24.59M) |
Cognition Therapeutics, Inc.
NASDAQ:CGTX
Intrinsic Alpha fair value
Locked
Current Price
$0.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.